title: A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.
abstract: OBJECTIVE
  To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive-compulsive disorder (OCD).
  
  
  METHODS
  The study was an 8-week pilot double-blind randomized clinical trial. Forty-two adult outpatients who met the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria for OCD based on the structured clinical interview participated in the trial. In this study, patients were randomly assigned to receive either ondansetron (4 mg) plus fluoxetine or fluoxetine (20 mg/day) plus placebo.
  
  
  RESULTS
  The results showed a significant difference between two groups in the treatment of OCD (based on t-test). There was not any significant difference between the two groups in terms of observed side effects.
  
  
  CONCLUSIONS
  The results of this study show that ondansetron has positive effects on obsession and compulsion which start two weeks after the beginning of the treatment.
authors.affiliation: Department of Anesthesiology, Jundishapur University of Medical Sciences, Ahwaz, Iran.
authors.forename: Farhad
authors.initials: F
authors.lastname: Soltani
authors.forename: Mehdi
authors.initials: M
authors.lastname: Sayyah
authors.forename: Fariba
authors.initials: F
authors.lastname: Feizy
authors.forename: Alireza
authors.initials: A
authors.lastname: Malayeri
authors.forename: Amir
authors.initials: A
authors.lastname: Siahpoosh
authors.forename: Ismail
authors.initials: I
authors.lastname: Motlagh
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D007406:Interview, Psychological; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D017294:Ondansetron / Q000009:adverse effects* / Q000627:therapeutic use*; D010045:Outpatients; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D012702:Serotonin Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005473:Fluoxetine; D017294:Ondansetron; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors